| Literature DB >> 28929116 |
Beata Szymańska1, Ewa Sawicka1, Anna Guzik1, Romuald Zdrojowy2, Anna Długosz1.
Abstract
BACKGROUND: The interaction of environmental factors with genetic susceptibility and detoxification level seems to be an important causative factor in bladder cancer (BC). The aim of this study was to look for a BC marker panel which reflects the environmental risk. The nuclear matrix protein 22 (NMP22), bladder cancer-4 (BLCA-4), and total level proteins NMP22 and BLCA-4 (NMBL) in BC patients with genetic predisposition NAT2 (classified as slow acetylators, SA), DNA damage (8-OHdG), and detoxification by isoenzyme GSTπ activity were measured.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28929116 PMCID: PMC5591903 DOI: 10.1155/2017/9643139
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Demographic and clinical data for the BC patients and the control.
| Patients | |
| Total number ( | 91 |
| Male/female | 74/17 |
| Age (years) (mean ± SD) | 68 ± 9.5 |
| Smokers number | 64 (75.3%) |
| Clinical grading | |
| Ta | 43 (45.3%) |
| T1 | 31 (34.1%) |
| T2 | 10 (11%) |
| TIS | 7 (7.7%) |
| Clinical staging | |
| G1 | 40 (47.6%) |
| G2 | 41 (48.8%) |
| G3 | 3 (3.6%) |
| Controls total number ( | 25 |
| Male/female | 18/7 |
| Age (years) (mean ± SD) | 65 ± 6.9 |
| Smokers number | 19 (76%) |
Results from the questionnaire of patients with BC.
| Factor risk of BC | Patients with BC ( |
|---|---|
| Smoker patients | 75.4% ( |
| Living in the city | 71% ( |
| Contact with pesticides | 34.1% ( |
| Exposure to chemicals | 13.4% ( |
Mean values of studied parameters in examined groups.
| NMP22 | BLCA-4 | NMBL | GST | 8-OHdG | |
|---|---|---|---|---|---|
| [ng/mg cr.] | [ng/mg cr.] | [ng/mg cr.] | [ng/mg cr.] | [ng/mg cr.] | |
|
| |||||
|
| 10.846 | 3.015 | 14.454 | 22.545 | 18.914 |
| SD | 8.312 | 3.535 | 11.919 | 29.878 | 15.468 |
|
| 91 | 63 | 63 | 91 | 63 |
|
| |||||
|
| |||||
|
| 5.147 | 0.878 | 6.026 | 4.210 | 12.393 |
| SD | 2.025 | 0.477 | 2.305 | 3.429 | 3.682 |
|
| 25 | 25 | 25 | 25 | 25 |
|
| |||||
|
| |||||
|
| 10.746 | 3.691 | 18.750 | 28.517 | 21.577 |
| SD | 8.205 | 5.295 | 22.076 | 29.554 | 20.322 |
|
| 17 | 10 | 10 | 17 | 10 |
|
| |||||
|
| |||||
|
| 10.285 | 2.887 | 13.655 | 21.174 | 18.441 |
| SD | 6.689 | 3.153 | 8.990 | 25.816 | 14.559 |
|
| 74 | 53 | 53 | 74 | 53 |
|
| |||||
|
| |||||
|
| 11.054 | 3.500 | 15.519 | 23.230 | 21.486■ |
| SD | 9.551 | 4.027 | 13.819 | 31.648 | 17.538 |
|
| 64 | 43 | 43 | 64 | 43 |
|
| |||||
|
| |||||
|
| 10.565 | 2.337 | 12.825 | 24.292 | 14.340 |
| SD | 3.987 | 2.032 | 6.119 | 28.205 | 8.486 |
|
| 21 | 14 | 14 | 21 | 14 |
∗: statistically significant difference in comparison to control group; ■: between smokers and nonsmokers; : mean; SD: standard deviation; n: number of cases.
Figure 1(a) BLCA-4, (b) GSTπ, and (c) 8-OHdG in tumor stage (T), in tumor grade (G), and in control group (C). (a) ∗: statistically significant difference between subtypes Ta/T1, Ta/T2, Ta/TIS; G1/G2. (b) ∗: statistically significant differences between subtypes Ta/T1, Ta/T2, TIS/T1, TIS/T2; G1/G2, G1/G3. (c) ∗: statistically significant differences between subtypes Ta/TIS, Ta/T2.
Analysis of genotype and acetylation status in BC patients.
| Genotype | Acetylation status |
|
|---|---|---|
|
| ||
|
| Fast | 8 (8.8) |
|
| Fast | 11 (12.1) |
|
| Intermediate | 17 (18.7) |
|
| Intermediate | 1 (1.0) |
|
| Slow | 16 (17.6) |
|
| Slow | 26 (28.6) |
|
| Slow | 3 (3.3) |
|
| Slow | 4 (4.4) |
|
| Slow | 5 (5.5) |
Mean value of markers at various NAT2 acetylators.
| NAT2 acetylation status | NMP22 | BLCA-4 | NMBL | GST | 8-OHdG |
|---|---|---|---|---|---|
|
|
| ||||
|
| 11.757 | 3.087 | 15.097 | 23.542 | 19.905 |
| SD | 9.257 | 3.448 | 13.154 | 32.732 | 15.497 |
|
| 54 | 42 | 42 | 54 | 42 |
|
| |||||
|
|
| ||||
|
| 10.093 | 3.011 | 14.328 | 23.319 | 16.971 |
| SD | 7.265 | 4.194 | 9.812 | 27.805 | 17.032 |
|
| 29 | 17 | 17 | 29 | 17 |
|
| |||||
|
|
| ||||
|
| 7.425 | 2.272 | 8.390 | 13.016 | 16.911 |
| SD | 2.517 | 1.106 | 1.660 | 12.627 | 9.522 |
|
| 8 | 4 | 4 | 8 | 4 |
The correlations between examined parameters in the group of slow acetylators (SA).
| Correlations in SA group |
|
|
|---|---|---|
| BLCA-4/GST |
|
|
| BLCA-4/T ( |
|
|
| NMBL/GST |
|
|
| NMBL/T ( |
|
|
| GST |
|
|
| GST |
|
|
| 8-OHdG/smoking |
|
|
| 8-OHdG/T ( |
|
|
| 8-OHdG/NMP22 |
|
|
|
|
|
|
| 8-OHdG/NMBL |
|
|
| 8-OHdG/GST |
|
|
|
|
|
|
| 8-OHdG/NMBL |
|
|
| BLCA-4/GST |
|
|
| NMBL/GST |
|
|
| 8-OHdG/NMP22 |
|
|
| 8-OHdG/GST |
|
|
SA: slow acetylation; R: Spearman correlation coefficient; p: level of significance; ∗: correlation in smokers SA group.
Evaluated indicators for assessing the reliability of diagnostic tests used in analysis (measures of association and measure of effect) in the whole BC and SA subgroups.
| Index | NMP22 | BLCA-4 | NMBL | GST | 8-OHdG | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| BC | SA | BC | SA | BC | SA | BC | SA | BC | SA | |
| Sensitivity [%] | 57 | 71 | 65 | 69 | 64 | 57 | 81 | 91 | 32 | 55 |
| Specificity [%] | 96 | 80 | 88 | 88 | 96 | 100 | 72 | 72 | 100 | 84 |
| ACC [%] | 66 | 75 | 72 | 76 | 73 | 74 | 79 | 84 | 51 | 66 |
| PPV [%] | 98 | 86 | 93 | 91 | 98 | 100 | 91 | 85 | 100 | 82 |
| NPV [%] | 38 | 63 | 50 | 63 | 51 | 58 | 51 | 82 | 37 | 53 |
| LR(+) | 14.286 | 3.571 | 5.423 | 5.754 | 15.873 | — | 2.904 | 3.231 | — | 3.423 |
| LR(−) | 0.446 | 0.357 | 0.397 | 0.352 | 0.380 | 0.429 | 0.259 | 0.132 | 0.683 | 0.539 |
| AUC | 0.836 | 0.818 | 0.830 | 0.835 | 0.858 | 0.862 | 0.790 | 0.866 | 0.637 | 0.706 |
| Youden index | 0.53 | 0.56 | 0.53 | 0.57 | 0.59 | 0.60 | 0.53 | 0.62 | 0.32 | 0.39 |
| Cut-off point | 8.53 | 8.529 | 1.403 | 1.4 | 9.740 | 10.45 | 4.342 | 4.38 | 18.17 | 15.322 |
ACC: accuracy; PPV: positive predictive value; NPV: negative predictive value; LR(+): positive likelihood ratio; (LR−): negative likelihood ratio; AUC: area under the ROC curve; Youden index (0-1) showing the relationship between sensitivity and specificity tests.
Figure 2Receiving operating characteristic (ROC) analysis of NMP22, BLCA-4, NMBL, GSTπ, and 8-OHdG level in whole BC group (a) and SA subgroup (b).